Polaris AI Pharma

At a glance

Polaris AI Pharma filed 24 disclosures in the last 12 months, including 2 5% holder, 1 buyback and 1 issuance. The most recent key filing was on Jul 24.

Revenue for 2025 was ₩55.5B, down 6.8% on 2024. Operating margin was 5.7% against 0.3% a year earlier. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩28.4B and operating profit of ₩1.4B.

The 2025 annual report lists 167 employees with an average tenure of 8.1 years and average pay of ₩51.6M, #1379 of 1,829 listed companies by average pay. Its 18 directors and auditors were paid ₩161M each on average. It paid no cash dividend for 2025. (주)폴라리스오피스 and related parties held 29.50% at year end.

From the 2025 annual report

Staff: 167 (111 men, 56 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩8.6B. Directors and auditors: 18, paid ₩2.9B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)폴라리스오피스 holds 7.52%; with 3 related parties the group holds 29.50% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 한미회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary